EMBR-22. RATIONAL DEVELOPMENT OF SYNERGISTIC THERAPIES ALONGSIDE BMI1 INHIBITION FOR GROUP 3 MEDULLOBLASTOMA

Medulloblastoma (MB) is the most common pediatric brain tumor. Of its four distinct molecular subgroups, Group 3 MBs are associated with increased risk of recurrence, metastasis and overall poor patient outcome. In recent years, small molecule inhibitors targeting BMI1 have shown to be efficacious a...

Descripción completa

Detalles Bibliográficos
Autores principales: Bakhshinyan, David, Adile, Ashley A, Venugopal, Chitra, Brown, Kevin, Chan, Katherine, Qazi, Maleeha A, Chokshi, Chirayu, Gwynne, William D, Tieu, David, Moffat, Jason, Singh, Sheila
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Embryonal Tumors
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8168109/
http://dx.doi.org/10.1093/neuonc/noab090.040

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8168109/
http://dx.doi.org/10.1093/neuonc/noab090.040

Ejemplares similares